Fulgent Genetics Inc Dossier
|
SectorHealth Care IndustryHealth Care Providers & Services Beta (adjusted)0.93 Intrinsic Value $21.25median of 2 methodsbased on filings through 30 Jun 2026 Market Price $21.30Price as of 1 Oct 2026 Near fair valueIntrinsic value is 0% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $586.1M Enterprise Value $560.2M Shares Outstanding 29.5M diluted Next Earnings Date6 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Fulgent Genetics is undergoing a critical strategic transition from a high-volume COVID-19 testing provider to a diversified precision medicine company. While its core laboratory services business faces near-term headwinds from customer concentration transitions (with its largest customer shifting testing in-house), the company's biopharma services segment is showing robust year-over-year growth. Crucially, Fulgent maintains an exceptionally strong balance sheet with over $600 million in cash and marketable securities, providing a significant margin of safety and funding its therapeutic pipeline (including FID-007 and FID-022) without immediate dilution risk. However, near-term profitability remains pressured by elevated integration and R&D expenses, justifying a Hold rating until clinical milestones or revenue stabilization are achieved. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$15.00 Mean target$18.50 High · most bullish analyst$22.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $15.0015% The bear case is triggered by further customer attrition in the precision diagnostics segment, clinical setbacks or safety concerns in the FID-007 trials, and prolonged delays in receiving the anticipated $106 million IRS tax refund, leading to accelerated cash burn. Base CaseCentral scenario $18.5060% Matches the consensus meanThe base case assumes Fulgent successfully stabilizes its core diagnostics revenue around the guided $350 million for FY 2026, while keeping its therapeutic development spend disciplined at approximately $26 million. The stock remains supported by its massive cash cushion, trading near its book value. Bull CaseUpside scenario $22.0025% The bull case is driven by rapid clinical validation of the therapeutic pipeline, specifically positive Phase 2/3 data for FID-007 in head and neck cancer, combined with successful integration of the Bako Diagnostics and StrataDX acquisitions. This would accelerate the transition to a high-margin precision medicine model and drive significant multiple expansion. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |